Trial reportBritish journal of cancer1996
Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.
Trial report in British journal of cancer, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00005908 (A Pilot Trial of Sequential Primary), which is not on this map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Trial of Sequential Primary (Neoadjuvant) Combination Chemotherapy With Docetaxel/Capecitabine (TX) and Doxorubicin/Cyclophosphamide (AC) in Primary Breast Cancer With Evaluation of Chemotherapy Effects on Gene Expression
Who cites it
38 citing papers in PubMed, 193 citations in OpenAlex.
- Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.Breast cancer research and treatment · 2011Trial
- The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer.British journal of cancer · 2010Trial
- Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.Breast cancer research : BCR · 2008Trial
- Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.Clinical drug investigation · 2006Trial
- Magnetic resonance imaging-based artificial intelligence model predicts neoadjuvant therapy response in triple-negative breast cancer.Diagnostic and interventional radiology (Ankara, Turkey) · 2026Article
- Is Ki-67 Really Useful as a Predictor for Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer?Indian journal of surgical oncology · 2024Article
- Locally Advanced Breast Cancer: Response Evaluation to Neoadjuvant Chemotherapy by Clinico-Histopathological Parameters and Molecular Imaging.Indian journal of surgical oncology · 2023Article
- Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer.Virchows Archiv : an international journal of pathology · 2016Article
- Correlation between the expression of S100A4 and the efficacy of TAC neoadjuvant chemotherapy in breast cancer.Experimental and therapeutic medicine · 2015Article
- Evaluation of biomarker changes after administration of various neoadjuvant chemotherapies in breast cancer.International journal of clinical and experimental pathology · 2015Article
- Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy.Pathology oncology research : POR · 2015Article
- Evaluation and Validation of Neo-Adjuvant Response Index (NRI) and It's Correlation with Various Predictive Biomarkers and RECIST in Locally Advanced Breast Cancer.Indian journal of surgical oncology · 2014Article
- Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy?BioMed research international · 2014Article
- Prognostic value of proliferation markers expression in breast cancer.Medical oncology (Northwood, London, England) · 2013Article
- The mitochondrial transport protein SLC25A43 affects drug efficacy and drug-induced cell cycle arrest in breast cancer cell lines.Oncology reports · 2013Article
- Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.Breast cancer research and treatment · 2012Review
- Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.Medical oncology (Northwood, London, England) · 2011Article
- Ki-67 biomarker in breast cancer of Indian women.North American journal of medical sciences · 2011Article
- Immunohistochemical assessment of primary breast tumors and metachronous brain metastases, with particular regard to differences in the expression of biological markers and prognosis.Experimental and therapeutic medicine · 2010Article
- Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.Clinical Medicine Insights. Oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary chemotherapy in operable breast invasive carcinoma enables tumour reduction and conservative surgery. In order to search for one or more biological factors capable of predicting tumour behaviour under primary chemotherapy, and subsequent patient survival, an immunohistochemical study was performed with specific antibodies to p53, c-erbB-2 (Her-2/neu), Mib1 (antiKi-67), pS2, GST pi, oestrogen receptors (ERs) and progesterone receptors (PRs). Core biopsies, obtained before primary chemotherapy, were available from a series of 128 breast invasive carcinomas treated between January 1985 and April 1989, with a median follow-up of 93.3 months. Univariate statistical analysis showed that negative ER detection by immunohistochemistry (IHC) was highly correlated with chemosensitivity (P = 0.001). A high percentage of Mib1-positive tumour cells (> 40%), as well as initial tumour size less than 4 cm, were also correlated with tumour responsiveness to chemotherapy (P = 0.009 and P = 0.03). By multivariate analysis IHC-ER, Mib1 and initial tumour size were independent predictors, the last parameter being the most important. Concerning subsequent patient survival, c-erbB-2 overexpression, as detected by IHC, was significant with respect to overall survival (OS) (P = 0.0006), disease-free interval (DFI) (P = 0.03) and metastasis-free interval (MFI) (P = 0.008) by univariate analysis. Furthermore, c-erbB-2 was the major independent prognostic factor for OS and MFI by multivariate analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.